双鹭药业(002038) - 2024 Q2 - 季度业绩预告

Financial Performance - Net profit attributable to shareholders of the listed company decreased significantly compared to the same period last year, with a profit of 31,716.41 million yuan in the previous year [4] - The decrease in net profit is mainly due to the fair value changes of held trading financial assets and available-for-sale financial assets, with a fair value change loss of approximately -118 million yuan in the first half of 2024, compared to a gain of 108 million yuan in the same period last year, resulting in a year-on-year decrease of 226 million yuan [5] Earnings Per Share - Basic earnings per share for the same period last year were 0.31 yuan per share [4] - Basic earnings per share after deducting non-recurring gains and losses were 0.19 yuan per share for the same period last year [4] Audit and Communication - The company has communicated with the annual audit accounting firm regarding the performance forecast, and there are no significant disagreements [6]